Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−13.15 USD
−101.87 M USD
7.00 M USD
6.21 M
About Kezar Life Sciences, Inc.
Sector
Industry
CEO
Christopher J. Kirk
Website
Headquarters
South San Francisco
Founded
2015
FIGI
BBG009DVZVV6
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of KZR is 7.62 USD — it has increased by 1.49% in the past 24 hours. Watch Kezar Life Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kezar Life Sciences, Inc. stocks are traded under the ticker KZR.
KZR stock has risen by 3.17% compared to the previous week, the month change is a −8.94% fall, over the last year Kezar Life Sciences, Inc. has showed a −14.38% decrease.
We've gathered analysts' opinions on Kezar Life Sciences, Inc. future price: according to them, KZR price has a max estimate of 18.00 USD and a min estimate of 11.00 USD. Watch KZR chart and read a more detailed Kezar Life Sciences, Inc. stock forecast: see what analysts think of Kezar Life Sciences, Inc. and suggest that you do with its stocks.
KZR stock is 2.41% volatile and has beta coefficient of 1.37. Track Kezar Life Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kezar Life Sciences, Inc. there?
Today Kezar Life Sciences, Inc. has the market capitalization of 54.65 M, it has decreased by −0.40% over the last week.
Yes, you can track Kezar Life Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Kezar Life Sciences, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
KZR earnings for the last quarter are −2.78 USD per share, whereas the estimation was −3.15 USD resulting in a 11.70% surprise. The estimated earnings for the next quarter are −2.73 USD per share. See more details about Kezar Life Sciences, Inc. earnings.
Kezar Life Sciences, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 800.00 K USD. In the next quarter, revenue is expected to reach 1.60 M USD.
KZR net income for the last quarter is −20.31 M USD, while the quarter before that showed −21.55 M USD of net income which accounts for 5.73% change. Track more Kezar Life Sciences, Inc. financial stats to get the full picture.
No, KZR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 58.00 employees. See our rating of the largest employees — is Kezar Life Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kezar Life Sciences, Inc. EBITDA is −94.90 M USD, and current EBITDA margin is −1.49 K%. See more stats in Kezar Life Sciences, Inc. financial statements.
Like other stocks, KZR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kezar Life Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kezar Life Sciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kezar Life Sciences, Inc. stock shows the sell signal. See more of Kezar Life Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.